Total Clarity Wealth Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Total Clarity Wealth Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500	Closed	–	–	363
2022 Q2	$0	Buy	+500	New	+$613	﹤0.01%	1020
2022 Q1	–	Sell	-500	Closed	-$1K	–	349
2021 Q4	$1K	Sell	500 -2,000	-80%	-$7.76K	﹤0.01%	948
2021 Q3	$12K	Buy	+2,500	New	+$7.4K	0.01%	628

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Total Clarity Wealth Management's CRVS Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of Corvus Pharmaceuticals (CRVS) in Q3 2022, closing a stake of 500 shares.

Total Clarity Wealth Management first reported a position in CRVS in Q3 2021 and held it in 3 quarters. The position peaked at $12K in Q3 2021. 48 funds tracked by Wall St. Rank hold CRVS as of Q3 2022.

Total Clarity Wealth Management reported no remaining Corvus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Total Clarity Wealth Management sold 500 Corvus Pharmaceuticals shares in Q3 2022.
Total Clarity Wealth Management first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 3 quarters.
Total Clarity Wealth Management's Corvus Pharmaceuticals position peaked at $12K in Q3 2021.
48 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.